-
Je něco špatně v tomto záznamu ?
A Simple Cervicovaginal Epigenetic Test for Screening and Rapid Triage of Women With Suspected Endometrial Cancer: Validation in Several Cohort and Case/Control Sets
C. Herzog, F. Marín, A. Jones, I. Evans, D. Reisel, E. Redl, L. Schreiberhuber, S. Paytubi, B. Pelegrina, Á. Carmona, P. Peremiquel-Trillas, J. Frias-Gomez, M. Pineda, J. Brunet, J. Ponce, X. Matias-Guiu, S. de Sanjosé, L. Alemany, A. Olaitan, M....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
IS-BRC-1215-20007
Department of Health - United Kingdom
NLK
Free Medical Journals
od 2004 do Před 1 rokem
Open Access Digital Library
od 1999-01-01
PubMed
36001862
DOI
10.1200/jco.22.00266
Knihovny.cz E-zdroje
- MeSH
- časná detekce nádoru metody MeSH
- epigeneze genetická MeSH
- infekce papilomavirem * diagnóza MeSH
- lidé MeSH
- nádory děložního čípku * diagnóza genetika MeSH
- nádory endometria * diagnóza genetika MeSH
- třídění pacientů MeSH
- vaginální stěr metody MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
PURPOSE: Endometrial cancer (EC) incidence has been rising over the past 10 years. Delays in diagnosis reduce survival and necessitate more aggressive treatment. We aimed to develop and validate a simple, noninvasive, and reliable triage test for EC to reduce the number of invasive diagnostic procedures and improve patient survival. METHODS: We developed a test to screen and triage women with suspected EC using 726 cervical smear samples from women with and without EC, and validated the test in 562 cervicovaginal samples using three different collection methods (cervical smear: n = 248; vaginal swab: n = 63; and self-collection: n = 251) and four different settings (case/control: n = 388; cohort of women presenting with postmenopausal bleeding: n = 63; a cohort of high-risk women with Lynch syndrome: n = 25; and a nested case/control setting from a screening cohort and samples taken up to 3 years before EC diagnosis: n = 86). RESULTS: We describe the Women's cancer risk IDentification - quantitative polymerase chain reaction test for Endometrial Cancer (WID-qEC), a three-marker test that evaluates DNA methylation in gene regions of GYPC and ZSCAN12. In cervical, self-collected, and vaginal swab samples derived from symptomatic patients, it detected EC with sensitivities of 97.2% (95% CI, 90.2 to 99.7), 90.1% (83.6 to 94.6), and 100% (63.1 to 100), respectively, and specificities of 75.8% (63.6 to 85.5), 86.7% (79.3 to 92.2), and 89.1% (77.8 to 95.9), respectively. The WID-qEC identified 90.9% (95% CI, 70.8 to 98.9) of EC cases in samples predating diagnosis up to 1 year. Test performance was similar across menopausal status, age, stage, grade, ethnicity, and histology. CONCLUSION: The WID-qEC is a noninvasive reliable test for triage of women with symptoms suggestive of ECs. Because of the potential for self-collection, it could improve early diagnosis and reduce the reliance for in-person visits.
Consortium for Biomedical Research in Cancer CIBERONC Carlos 3 Institute of Health Madrid Spain
Department of Clinical Science Center for Cancer Biomarkers CCBIO University of Bergen Bergen Norway
Department of Obstetrics and Gynaecology Haukeland University Hospital Bergen Norway
Department of Women's and Children's Health Karolinska Institutet Stockholm Sweden
Department of Women's Cancer University College London London United Kingdom
Division of Pathology Department of Laboratory Medicine Karolinska Institutet Stockholm Sweden
Hereditary Cancer Group Catalan Institute of Oncology IDIBGI Girona Spain
Institute for Biomedical Aging Research Universität Innsbruck Innsbruck Austria
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22032623
- 003
- CZ-PrNML
- 005
- 20230131151125.0
- 007
- ta
- 008
- 230120s2022 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1200/JCO.22.00266 $2 doi
- 035 __
- $a (PubMed)36001862
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Herzog, Chiara $u European Translational Oncology Prevention and Screening (EUTOPS) Institute, Universität Innsbruck, Innsbruck, Austria $u Institute for Biomedical Aging Research, Universität Innsbruck, Innsbruck, Austria $1 https://orcid.org/000000021572498X
- 245 12
- $a A Simple Cervicovaginal Epigenetic Test for Screening and Rapid Triage of Women With Suspected Endometrial Cancer: Validation in Several Cohort and Case/Control Sets / $c C. Herzog, F. Marín, A. Jones, I. Evans, D. Reisel, E. Redl, L. Schreiberhuber, S. Paytubi, B. Pelegrina, Á. Carmona, P. Peremiquel-Trillas, J. Frias-Gomez, M. Pineda, J. Brunet, J. Ponce, X. Matias-Guiu, S. de Sanjosé, L. Alemany, A. Olaitan, M. Wong, D. Jurkovic, EJ. Crosbie, AN. Rosenthal, L. Bjørge, M. Zikan, L. Dostalek, D. Cibula, K. Sundström, J. Dillner, L. Costas, M. Widschwendter
- 520 9_
- $a PURPOSE: Endometrial cancer (EC) incidence has been rising over the past 10 years. Delays in diagnosis reduce survival and necessitate more aggressive treatment. We aimed to develop and validate a simple, noninvasive, and reliable triage test for EC to reduce the number of invasive diagnostic procedures and improve patient survival. METHODS: We developed a test to screen and triage women with suspected EC using 726 cervical smear samples from women with and without EC, and validated the test in 562 cervicovaginal samples using three different collection methods (cervical smear: n = 248; vaginal swab: n = 63; and self-collection: n = 251) and four different settings (case/control: n = 388; cohort of women presenting with postmenopausal bleeding: n = 63; a cohort of high-risk women with Lynch syndrome: n = 25; and a nested case/control setting from a screening cohort and samples taken up to 3 years before EC diagnosis: n = 86). RESULTS: We describe the Women's cancer risk IDentification - quantitative polymerase chain reaction test for Endometrial Cancer (WID-qEC), a three-marker test that evaluates DNA methylation in gene regions of GYPC and ZSCAN12. In cervical, self-collected, and vaginal swab samples derived from symptomatic patients, it detected EC with sensitivities of 97.2% (95% CI, 90.2 to 99.7), 90.1% (83.6 to 94.6), and 100% (63.1 to 100), respectively, and specificities of 75.8% (63.6 to 85.5), 86.7% (79.3 to 92.2), and 89.1% (77.8 to 95.9), respectively. The WID-qEC identified 90.9% (95% CI, 70.8 to 98.9) of EC cases in samples predating diagnosis up to 1 year. Test performance was similar across menopausal status, age, stage, grade, ethnicity, and histology. CONCLUSION: The WID-qEC is a noninvasive reliable test for triage of women with symptoms suggestive of ECs. Because of the potential for self-collection, it could improve early diagnosis and reduce the reliance for in-person visits.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a třídění pacientů $7 D014218
- 650 _2
- $a časná detekce nádoru $x metody $7 D055088
- 650 _2
- $a vaginální stěr $x metody $7 D014626
- 650 12
- $a nádory endometria $x diagnóza $x genetika $7 D016889
- 650 _2
- $a epigeneze genetická $7 D044127
- 650 12
- $a nádory děložního čípku $x diagnóza $x genetika $7 D002583
- 650 12
- $a infekce papilomavirem $x diagnóza $7 D030361
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Marín, Fátima $u Hereditary Cancer Group, Catalan Institute of Oncology, IDIBELL, ONCOBELL Program, L'Hospitalet, Barcelona, Spain $u Consortium for Biomedical Research in Cancer-CIBERONC, Carlos III Institute of Health, Madrid, Spain $1 https://orcid.org/0000000335340091
- 700 1_
- $a Jones, Allison $u Department of Women's Cancer, University College London, London, United Kingdom
- 700 1_
- $a Evans, Iona $u Department of Women's Cancer, University College London, London, United Kingdom
- 700 1_
- $a Reisel, Daniel $u Department of Women's Cancer, University College London, London, United Kingdom
- 700 1_
- $a Redl, Elisa $u European Translational Oncology Prevention and Screening (EUTOPS) Institute, Universität Innsbruck, Innsbruck, Austria $u Institute for Biomedical Aging Research, Universität Innsbruck, Innsbruck, Austria
- 700 1_
- $a Schreiberhuber, Lena $u European Translational Oncology Prevention and Screening (EUTOPS) Institute, Universität Innsbruck, Innsbruck, Austria $u Institute for Biomedical Aging Research, Universität Innsbruck, Innsbruck, Austria $1 https://orcid.org/0000000330659888
- 700 1_
- $a Paytubi, Sonia $u Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain $1 https://orcid.org/000000025392953X
- 700 1_
- $a Pelegrina, Beatriz $u Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain $1 https://orcid.org/0000000298321165
- 700 1_
- $a Carmona, Álvaro $u Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain $1 https://orcid.org/0000000254426117
- 700 1_
- $a Peremiquel-Trillas, Paula $u Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain $1 https://orcid.org/0000000286361725
- 700 1_
- $a Frias-Gomez, Jon $u Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
- 700 1_
- $a Pineda, Marta $u Hereditary Cancer Group, Catalan Institute of Oncology, IDIBELL, ONCOBELL Program, L'Hospitalet, Barcelona, Spain $u Consortium for Biomedical Research in Cancer-CIBERONC, Carlos III Institute of Health, Madrid, Spain $1 https://orcid.org/0000000254035845
- 700 1_
- $a Brunet, Joan $u Hereditary Cancer Group, Catalan Institute of Oncology, IDIBELL, ONCOBELL Program, L'Hospitalet, Barcelona, Spain $u Consortium for Biomedical Research in Cancer-CIBERONC, Carlos III Institute of Health, Madrid, Spain $u Hereditary Cancer Group, Catalan Institute of Oncology, IDIBGI, Girona, Spain $1 https://orcid.org/0000000319453512
- 700 1_
- $a Ponce, Jordi $u Consortium for Biomedical Research in Cancer-CIBERONC, Carlos III Institute of Health, Madrid, Spain $u Department of Gynecology, Hospital Universitari de Bellvitge, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain $1 https://orcid.org/0000000206132261
- 700 1_
- $a Matias-Guiu, Xavier $u Consortium for Biomedical Research in Cancer-CIBERONC, Carlos III Institute of Health, Madrid, Spain $u Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain
- 700 1_
- $a de Sanjosé, Silvia $u ISGlobal, Barcelona, Spain
- 700 1_
- $a Alemany, Laia $u Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain $u Consortium for Biomedical Research in Epidemiology and Public Health-CIBERESP, Carlos III Institute of Health, Madrid, Spain
- 700 1_
- $a Olaitan, Adeola $u University College Hospital, London, United Kingdom
- 700 1_
- $a Wong, Michael $u University College Hospital, London, United Kingdom $1 https://orcid.org/0000000221681111
- 700 1_
- $a Jurkovic, Davor $u University College Hospital, London, United Kingdom
- 700 1_
- $a Crosbie, Emma J $u Department of Obstetrics and Gynaecology, Manchester Academic Health Science Center, St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester, United Kingdom $u Gynaecological Oncology Research Group, Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom $1 https://orcid.org/0000000302848630
- 700 1_
- $a Rosenthal, Adam N $u Department of Women's Cancer, University College London, London, United Kingdom
- 700 1_
- $a Bjørge, Line $u Department of Obstetrics and Gynaecology, Haukeland University Hospital, Bergen, Norway $u Department of Clinical Science, Center for Cancer Biomarkers CCBIO, University of Bergen, Bergen, Norway $1 https://orcid.org/0000000202402770
- 700 1_
- $a Zikan, Michal $u Department of Gynecology and Obstetrics, Charles University in Prague, First Faculty of Medicine and Bulovka University Hospital, Czech Republic $1 https://orcid.org/0000000152668895
- 700 1_
- $a Dostalek, Lukas $u Department of Obstetrics and Gynecology, First Faculty of Medicine, Gynaecologic Oncology Center, Charles University in Prague, General University Hospital in Prague, Prague, Czech Republic $1 https://orcid.org/0000000301514559
- 700 1_
- $a Cibula, David $u Department of Obstetrics and Gynecology, First Faculty of Medicine, Gynaecologic Oncology Center, Charles University in Prague, General University Hospital in Prague, Prague, Czech Republic $1 https://orcid.org/0000000163879356
- 700 1_
- $a Sundström, Karin $u Division of Pathology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden $1 https://orcid.org/0000000268650224
- 700 1_
- $a Dillner, Joakim $u Division of Pathology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden $1 https://orcid.org/0000000185886506
- 700 1_
- $a Costas, Laura $u Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain $u Consortium for Biomedical Research in Epidemiology and Public Health-CIBERESP, Carlos III Institute of Health, Madrid, Spain
- 700 1_
- $a Widschwendter, Martin $u European Translational Oncology Prevention and Screening (EUTOPS) Institute, Universität Innsbruck, Innsbruck, Austria $u Institute for Biomedical Aging Research, Universität Innsbruck, Innsbruck, Austria $u Department of Women's Cancer, University College London, London, United Kingdom $u Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden $1 https://orcid.org/0000000277788380
- 773 0_
- $w MED00002596 $t Journal of clinical oncology : official journal of the American Society of Clinical Oncology $x 1527-7755 $g Roč. 40, č. 33 (2022), s. 3828-3838
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36001862 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230120 $b ABA008
- 991 __
- $a 20230131151121 $b ABA008
- 999 __
- $a ok $b bmc $g 1891406 $s 1183958
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2022 $b 40 $c 33 $d 3828-3838 $e 20220824 $i 1527-7755 $m Journal of clinical oncology $n J. clin. Oncol. $x MED00002596
- GRA __
- $a IS-BRC-1215-20007 $p Department of Health $2 United Kingdom
- LZP __
- $a Pubmed-20230120
